On June 18, 2025, the U.S. Food and Drug Administration (FDA) officially approved Yeztugo®—the brand name for lenacapavir, developed by Gilead Sciences—as the world’s first and only biannual injectable PrEP (Pre-Exposure Prophylaxis) for HIV prevention. This marks a major milestone in medical advancement that has drawn global attention. The approval is based on international clinical
Tag Archives: Injectable PrEP
06
Feb
Feb
In recent years, medical innovations have advanced rapidly, especially in the prevention of HIV infection. One of the latest breakthroughs is Injectable PrEP, or Cabotegravir Long-Acting (CAB-LA), a new, convenient, and highly effective option for HIV prevention. Currently, Injectable PrEP has been approved by the World Health Organization (WHO) and the U.S. Food and Drug